GlassScriptPhysician profile
Roula H Daher
NPI 1689938789
$3,743.25
in general payments reported to CMS, 2019-2025
19 companies · $973 in 2025
The $973 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $387 · 2021: $903 · 2022: $525 · 2023: $288 · 2024: $129 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.28 |
| Education | $208.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,580.26 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $349.43 | 2020-2025 | Dupixent |
| Csl Behring | $334.40 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Astrazeneca Pharmaceuticals LP | $323.82 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Optinose US, INC. | $186.69 | 2019-2025 | |
| Genentech USA, INC. | $174.28 | 2019-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.92 | 2019-2022 | |
| Pharming Healthcare, INC. | $101.34 | 2023-2025 | Ruconest |
| Genzyme Corporation | $95.12 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $74.16 | 2025 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Pfizer INC. | $50.29 | 2019-2024 | |
| Ars Pharmaceuticals Operations, INC. | $48.77 | 2025 | Neffy |
| Kaleo, INC. | $47.99 | 2022-2023 | Auvi-Q |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $42.12 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Cycle Pharmaceuticals INC | $34.95 | 2025 | Sajazir |
| Ionis Pharmaceuticals, INC. | $21.72 | 2025 | |
| Galderma Laboratories, L.P. | $16.15 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roula Daher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.